arrow
D

Daniela Dornelles Rosa

hospital moinhos de vento
H指数:30
被引数:2,823

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Interpretable machine learning models for oncotypedDX® prediction using clinicopathologic data: a brazilian cohort study

基于临床病理数据构建可解释机器学习模型预测OncotypedDX®分型:一项巴西队列研究

2026-10-260
OAAI
Role of tumor-infiltrating lymphocytes in early-stage triple-negative breast cancer treated with KEYNOTE-522 in real-world setting
2026-08-140
OA
Survival After Multimodal Treatment for Breast Cancer in Brazil: The Predominant Role of Clinical Stage and Treatment Response

巴西乳腺癌多模式治疗后的生存情况:临床分期和治疗反应的主导作用

2026-05-120
OAAI
OP13 Prioritizing Real-World Data In Next-Generation Health Technology Assessment: Insights From Oncotype DX Breast Recurrence Score® And Chemotherapy Recommendations For Breast Cancer In Brazil
2026-01-310
OA
Sexual dysfunction in Brazilian women undergoing adjuvant endocrine therapy for breast cancer: prevalence and associated factors

接受乳腺癌辅助内分泌治疗的巴西妇女的性功能障碍: 患病率和相关因素

2026-01-240
OAAI
Impact of public vs. private insurance coverage on quality of life of women with early-stage estrogen receptor-positive breast cancer

公共与私人保险覆盖对早期雌激素受体阳性乳腺癌女性生活质量的影响

2025-12-050
OAAI
Employment Status Among Brazilian Women With Estrogen Receptor-Positive Nonmetastatic Breast Cancer

巴西雌激素受体阳性非转移性乳腺癌女性患者的就业状况

2025-10-290
OAAI
Non-metastatic breast cancer in older patients in Brazil: Adherence to endocrine therapy, quality of life, and sexual health

巴西老年非转移性乳腺癌患者:内分泌治疗的依从性、生活质量及性健康

2025-09-120
PRE
Cancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 study

对于符合辅助性细胞周期蛋白依赖性激酶4和6抑制剂条件但经Oncotype Dx免于辅助化疗的患者的癌症结局:一项多中心回顾性GBECAM 0520研究

2025-08-050
PREAI
Real-World Data on First-Line Treatment of Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer in Brazil (BRAVE Study)

Werutsky, G.; Rosa, D.D.; Reinert, T.; Barroso-Sousa, R.; Resende, H.; Signorini, P.; Cronemberger, E.; Fagundes, J.G.M.; Leal, J.H.S.; Guimarães, M.B.; et al. 巴西激素受体阳性、HER2阴性转移性乳腺癌一线治疗的真实世界数据(BRAVE研究)。Clin. Breast Cancer 2025, S1526820925001624. [Google Scholar] [CrossRef] [PubMed]

2025-05-270
OAAI
Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/GBECAM 0123 study

早期三阴性乳腺癌患者接受帕博利珠单抗联合化疗治疗后的免疫相关不良事件:Neo-Real/GBECAM 0123研究的真实世界数据

2025-04-100
OAAI
Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study
2025-02-030
PRE
Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer
2024-08-142
OAAI
Cancer health disparities among patients with early-stage estrogen receptorpositive (ER plus ) breast cancer treated in public or private practices in Brazil
2024-05-020
PRE
Dose-dense versus 3-weekly AC during Neoadjuvant Chemoimmunotherapy for EarlyStage Triple-Negative Breast Cancer (TNBC): a Real-World Safety and Efficacy Data Analysis
2024-05-020
PRE
Suboptimal adherence to adjuvant endocrine therapy (ET) in Brazilian women with early-stage estrogen receptor-positive (ER plus ) breast cancer
2024-05-021
PRE
The Utility of Oncotype DX in Grade 1 Hormone Receptor-Positive Early Breast Cancer: Insights from a Multicentric Real-World Data Study
2024-05-020
PRE